Literature DB >> 18073153

A case series of macrolide treatment failures in community acquired pneumonia.

P B Iannini1, J A Paladino, B Lavin, M E Singer, J J Schentag.   

Abstract

This was a retrospective, multi-center study of patients admitted to hospital with community-acquired pneumonia, caused by Streptococcus pneumoniae, after failing to respond to >2 days of outpatient macrolide therapy. 122 cases, treated between 2000-2004, were enrolled from 31 North American sites between January 2004 - March 2005. Non-susceptible isolates (predominately low-level resistance: erythromycin MICs of 1-16 mcg/ml) were recovered from 87 patients (71%). Bacteremia was present in 63 patients (52%). The in-hospital mortality rate was 5.7 %; all 7 patients who died were bacteremic, 6 had a non-susceptible isolate. We report here the largest series of macrolide failures published to date. The patients were notable for their high rates of macrolide resistance, bacteremia, and mortality. High-level macrolide resistance remains rare among US patients failing outpatient macrolides. The majority of cases and virtually all of the mortality occurred in patients with low-level resistant strains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073153     DOI: 10.1179/joc.2007.19.5.536

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  10 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy.

Authors:  Simone Gattarello
Journal:  Curr Infect Dis Rep       Date:  2015-10       Impact factor: 3.725

Review 3.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

4.  Human antimicrobial peptide LL-37 induces MefE/Mel-mediated macrolide resistance in Streptococcus pneumoniae.

Authors:  Dorothea Zähner; Xiaoliu Zhou; Scott T Chancey; Jan Pohl; William M Shafer; David S Stephens
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

5.  Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.

Authors:  Lotta Siira; Merja Rantala; Jari Jalava; Antti J Hakanen; Pentti Huovinen; Tarja Kaijalainen; Outi Lyytikäinen; Anni Virolainen
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

Review 6.  Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia.

Authors:  Brad Spellberg; George H Talbot; Eric P Brass; John S Bradley; Helen W Boucher; David N Gilbert
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

7.  Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; Navneet Singh; Narayan Mishra; G C Khilnani; J K Samaria; S N Gaur; S K Jindal
Journal:  Lung India       Date:  2012-07

8.  Treatment of Community-Acquired Pneumonia: A Case Report and Current Treatment Dilemmas.

Authors:  Glenn Harnett
Journal:  Case Rep Emerg Med       Date:  2017-06-15

9.  Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis.

Authors:  Gregory Hess; Jerrold W Hill; Monika K Raut; Alan C Fisher; Samir Mody; Jeff R Schein; Chi-Chang Chen
Journal:  Adv Ther       Date:  2010-08-26       Impact factor: 3.845

Review 10.  Challenges in severe community-acquired pneumonia: a point-of-view review.

Authors:  Antoni Torres; James D Chalmers; Charles S Dela Cruz; Cristina Dominedò; Marin Kollef; Ignacio Martin-Loeches; Michael Niederman; Richard G Wunderink
Journal:  Intensive Care Med       Date:  2019-01-31       Impact factor: 17.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.